cache/95f46ace9ca61952a1c5e67c3d053ae370df58b05d3a88569a9f2e291e6fe27e

CH:ASEPTCONN

Aseptconn AG

  • Privately Held

Company Overview

Metric
Company NameAseptconn AGLantronix, Inc.
SymbolLTRX
MSH IDCH:ASEPTCONNCOM:LANTRONIX
MarketPRIVATESTOCKS
SectorCommercial & Professional ServicesTechnology
IndustryHealthcare & Health ServicesCommunication Equipment
CountryCHUS
Stage
Employee Count11357
Websiteaseptconn.chlantronix.com
LinkedIn
Founders

Market Metrics

Metric
Market Cap140.93M
Enterprise Value
Monthly Web Traffic13.54K34.53K
Web Traffic Growth5.00-0.24
Valuation
Raised Capital2M

Financial Performance

Metric
Revenue160.33M
Revenue (LTM)
Revenue (NTM)
Gross Profit57.34M
EBITDA6.03M
Operating Income-1.45M
Net Income-4.52M
EPS-0.12
Diluted EPS-0.12
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Growth Metrics

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Profitability Ratios

Metric
Gross Profit Margin0.42
Operating Profit Margin-0.01
EBITDA Margin0.04
Net Profit Margin-0.03
Return on Equity-0.06
Return on Assets-0.03
Return on Capital Employed-0.02

Valuation Multiples

Metric
P/E Ratio-24.93
P/B Ratio2.98
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio1.04
EV Multiple105.64

Operational Metrics

Metric
Days Sales Outstanding84.71
Days Payables Outstanding43.88
Days Inventory Outstanding194.20
Operating Cycle279.25
Cash Conversion Cycle235.69
Asset Turnover1.18

Cash Flow Metrics

Metric
Operating Cash Flow18.62M
Free Cash Flow17.14M
Cash Flow to Debt1.15
Operating Cash Flow/Sales0.16
Free Cash Flow Yield0.04

Balance Sheet Metrics

Metric
Cash & Equivalents26.24M
Accounts Receivable-3.60M
Inventory27.70M
Goodwill27.82M
Debt to Capitalization0.27
Debt to Assets0.20
Current Ratio2.03
Quick Ratio2.03

Efficiency Metrics

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue0.05
R&D to Revenue0.15
SG&A to Revenue0.26